LoadingLoadingLoadingNet selling: insiders sold $26.8M and bought $3K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
SRS Investment Mgmt
$42.5M
bought
Lakewood
$18.5M
added
Sells/Trims (1)
D.E. Shaw
$26.2M
trimmed
No tracked top-trader positions in CRL as of Oct 24, 09:34 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Period ending
Jun 27, 2026
Earnings per share
$2.72 expected
Estimates as of Oct 23, 2026
EPS expected
$2.92 to $3.09
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 27, 2026 | Aug 5, 2026 | $3.02 / $2.72Alpha Vantage | +11.03% beat | $1.00B No estimateSEC filing | Unavailable |
| Mar 28, 2026 | May 7, 2026 | $2.06 / $1.95Alpha Vantage | +5.64% beat | $995.8M No estimateSEC filing | Unavailable |
| Dec 31, 2025 | Feb 18, 2026 | $2.39 / $2.33Alpha Vantage | +2.58% beat | $994.2M No estimate | Unavailable |
| Sep 27, 2025 | Nov 5, 2025 | $2.43 / $2.32Alpha Vantage | +4.74% beat | $1.00B No estimateSEC filing | Unavailable |
| Jun 28, 2025 | Aug 6, 2025 | $3.12 / $2.55Alpha Vantage | +22.35% beat | $1.03B No estimateSEC filing | Unavailable |
| Mar 29, 2025 | May 7, 2025 | $2.34 / $2.07Alpha Vantage | +13.04% beat | $984.2M No estimateSEC filing | Unavailable |
| Dec 31, 2024 | Feb 19, 2025 | $2.66 / $2.53Alpha Vantage | +5.14% beat | $1.00B No estimate | Unavailable |
| Sep 28, 2024 | Nov 6, 2024 | $2.59 / $2.42Alpha Vantage | +7.02% beat | $1.01B No estimateSEC filing | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.00B | $994.2M | $995.8M | $1.00B |
| Cost of what it sold | $666.1M | $686.4M | $716.5M | $640.7M |
| Gross profit | $338.8M | $307.9M | $279.3M | $363.4M |
| What it spent | ||||
| Sales and admin | $177.6M | $187.6M | $159.4M | $228.9M |
| Other operating costs | $27.4M | — | — | $14.6M |
| Total operating expenses | $205.0M | $187.6M | $159.4M | $243.5M |
| What was left | ||||
| Operating profit | $133.8M | $120.2M | $119.9M | $119.9M |
| Interest on debt | $25.4M | $23.8M | $26.7M | $30.3M |
| Profit before tax | $87.2M | -$294.1M | -$29.9M | $53.2M |
| Tax | $31.6M | -$17.8M | -$15.1M | $53.9M |
| Net profit | $54.4M | -$276.6M | -$14.8M | -$1.5M |
| EBITDA | $197.8M | -$192.0M | $64.0M | $150.8M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Thermo Fisher Scientific Q3 2026 Earnings Call Transcript
Leans bullishOct 21IQVIA schedules October 27 results for IQVIA Holdings stock
NeutralOct 20Citrini Research Names Charles River, Revvity in AI Drug Thesis
Leans bullishOct 20Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00
Leans bullishOct 20Leerink lifts target to USD 365.00 for Labcorp stock
NeutralOct 20Morgan Stanley lifts target for Charles River Laboratories stock to USD 340.00
BullishOct 20Charles River Laboratories International (CRL) Earnings Beat Puts Fair Value Back In Focus
BullishOct 18JPMorgan sets USD 345.00 target for Charles River Laboratories stock
NeutralOct 17
